Avinger, Inc. (NASDAQ: AVGR) recently conducted its Special Meeting of Stockholders on January 24, 2025, with the intention of addressing critical matters. However, the Company faced a setback as it failed to achieve a quorum during the meeting, thereby rendering it unable to conduct any business.
According to the Company’s bylaws, in the event of a lack of quorum at a stockholder meeting, the chairperson holds the authority to adjourn the meeting to a later date. Consequently, the Special Meeting has been rescheduled to take place on February 5, 2025, at 1:00 PM Pacific Time. The meeting will be convened at Avinger’s offices located at 400 Chesapeake Drive, Redwood City, California 94063.
Avinger, Inc. has diligently followed the necessary regulatory procedures in ensuring a transparent and fair decision-making process. The Company, led by Chief Executive Officer Jeffrey M. Soinski, remains committed to convening a successful meeting on the rescheduled date to address the matters at hand.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Avinger’s 8K filing here.
About Avinger
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
See Also
- Five stocks we like better than Avinger
- Dividend Payout Ratio Calculator
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What does consumer price index measure?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Despite Short-Term Risks Freeport McMoran Worth a Look
